Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15770914 | 0.90 | HSPB1 (0.51) | MAPTPOLBMEN1KMT2AL3MBTL1 | |
| SCHEMBL26631818 | 0.90 | TTR (0.48) | MAPTPOLBMEN1KMT2AL3MBTL1 | |
| SCHEMBL26631738 | 0.89 | MAPT (0.43) | MAPTPOLBMEN1KMT2AL3MBTL1 | |
| SCHEMBL15067957 | 0.86 | HSPB1 (0.47) | MAPTPOLBMEN1KMT2AL3MBTL1 | |
| SCHEMBL15972175 | 0.83 | POLB (0.51) | MAPTPOLBMEN1KMT2AL3MBTL1 | |
| SCHEMBL26631729 | 0.82 | ALDH1A1 (0.46) | MAPTPOLBMEN1KMT2AL3MBTL1 | |
| SCHEMBL29634822 | 0.80 | HPGD (0.52) | MAPTPOLBMEN1KMT2AL3MBTL1 | |
| SCHEMBL1953578 | 0.78 | POLB (0.61) | MAPTPOLBMEN1KMT2AL3MBTL1 | |
| SCHEMBL29634821 | 0.77 | SMN1; SMN2 (0.45) | MAPTPOLBMEN1KMT2AHTT | |
| SCHEMBL15067230 | 0.77 | HSPB1 (0.54) | MAPTMEN1KMT2AL3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092744-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | THE NATIONAL INSTITUTES OF PHARMACEUTICAL R&D CO., LTD (CN) | 2024-03-21 | — | — | US | disclosed |
| CN-114981275-B | Tricyclic compound, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2023-12-19 | — | — | CN | disclosed |
| EP-4273150-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | The National Institutes of Pharmaceutical R&D Co., Ltd (CN) | 2023-11-08 | — | — | EP | disclosed |
| EP-4273150-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | The National Institutes of Pharmaceutical R&D Co., Ltd (CN) | 2023-11-08 | — | — | EP | disclosed |
| CN-114981275-A | Tricyclic compound, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2022-08-30 | — | — | CN | disclosed |
| WO-2022143489-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2022-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092744-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GOT2, HADH, CYP4A11 | MAPT 2211/4885POLB 2116/4885MEN1 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.